Cargando…

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statist...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi, Mohammad, Bahari, Gholamreza, Markowski, Jarosław, Małecki, Andrzej, Łos, Marek J., Ghavami, Saeid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973848/
https://www.ncbi.nlm.nih.gov/pubmed/29872511
http://dx.doi.org/10.18632/oncotarget.25324
_version_ 1783326698493706240
author Hashemi, Mohammad
Bahari, Gholamreza
Markowski, Jarosław
Małecki, Andrzej
Łos, Marek J.
Ghavami, Saeid
author_facet Hashemi, Mohammad
Bahari, Gholamreza
Markowski, Jarosław
Małecki, Andrzej
Łos, Marek J.
Ghavami, Saeid
author_sort Hashemi, Mohammad
collection PubMed
description This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70–0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67–0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.
format Online
Article
Text
id pubmed-5973848
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59738482018-06-05 Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis Hashemi, Mohammad Bahari, Gholamreza Markowski, Jarosław Małecki, Andrzej Łos, Marek J. Ghavami, Saeid Oncotarget Review This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70–0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67–0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk. Impact Journals LLC 2018-05-15 /pmc/articles/PMC5973848/ /pubmed/29872511 http://dx.doi.org/10.18632/oncotarget.25324 Text en Copyright: © 2018 Hashemi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Hashemi, Mohammad
Bahari, Gholamreza
Markowski, Jarosław
Małecki, Andrzej
Łos, Marek J.
Ghavami, Saeid
Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title_full Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title_fullStr Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title_full_unstemmed Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title_short Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis
title_sort association of pdcd6 polymorphisms with the risk of cancer: evidence from a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973848/
https://www.ncbi.nlm.nih.gov/pubmed/29872511
http://dx.doi.org/10.18632/oncotarget.25324
work_keys_str_mv AT hashemimohammad associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis
AT baharigholamreza associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis
AT markowskijarosław associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis
AT małeckiandrzej associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis
AT łosmarekj associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis
AT ghavamisaeid associationofpdcd6polymorphismswiththeriskofcancerevidencefromametaanalysis